Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21598021 | 0.83 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL23189851 | 0.83 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL21605548 | 0.74 | — | — | |
| SCHEMBL30602991 | 0.73 | ALDH1A1 (0.43) | EPHX1GFERCA1CA12CA2 | |
| SCHEMBL30602966 | 0.69 | L3MBTL1 (0.39) | GFERCA1CA12CA2CA9 | |
| SCHEMBL8056750 | 0.69 | CHRM2 (0.39) | GFERCA1CA12CA2CA9 | |
| SCHEMBL21605563 | 0.69 | ACACB (0.51) | ACACBEPHX1DRD2KMT2A | |
| SCHEMBL23219326 | 0.69 | ACACB (0.51) | ACACBEPHX1DRD2KMT2A | |
| SCHEMBL8245984 | 0.68 | KDM4A (0.34) | CA1CA12CA2CA9KDM4A | |
| Hydrochloric Acid SCHEMBL23189724 | 0.68 | ESR1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281823-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-08 | — | — | US | disclosed |
| EP-3806958-B1 | 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-07 | — | — | EP | disclosed |
| EP-3807251-B1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-07 | — | — | EP | disclosed |
| EP-3807261-B1 | PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-13 | — | — | EP | disclosed |
| EP-3807261-B1 | PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-13 | — | — | EP | disclosed |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-31 | — | — | US | disclosed |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-31 | — | — | US | disclosed |
| US-11034658-B2 | Pyridinyl pyrazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-15 | — | — | US | disclosed |
| US-10975037-B2 | Phenyl substituted pyrazoles as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-13 | — | — | US | disclosed |
| US-10975057-B2 | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-13 | — | — | US | disclosed |
| CN-112566901-A | Phenyl-substituted pyrazoles as modulators of ROR γ t | 詹森药业有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-112334450-A | Phenyl and pyridyl substituted imidazoles as modulators of ROR γ t | 詹森药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-112292373-A | Pyridylpyrazoles as modulators of ROR γ t | 詹森药业有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-112292183-A | 6-aminopyridin-3-yl-pyrazoles as modulators of ROR γ t | 詹森药业有限公司 | 2021-01-29 | — | — | CN | disclosed |
| WO-2019243999-A1 | PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019244002-A1 | PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019244000-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019244001-A1 | 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034658-B2 | Pyridinyl pyrazoles as modulators of RORγT | RORC, RORB, RORA | ACACB 3910/4885EPHX1 1351/4885GFER 4117/4885 |
| US-20220281823-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT | RORC, RORB, RORA | ACACB 3485/4885EPHX1 834/4885GFER 4643/4885 |
| US-10975037-B2 | Phenyl substituted pyrazoles as modulators of RORγt | RORC, RORB, RORA | ACACB 4082/4885EPHX1 1753/4885GFER 3983/4885 |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | RORC, RORB, RORA | ACACB 3485/4885EPHX1 1149/4885GFER 4577/4885 |
| US-10975057-B2 | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT | RORC, RORA, RORB | ACACB 3098/4885EPHX1 1504/4885GFER 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.